Search results
Results from the WOW.Com Content Network
Androgen replacement therapy formulations and dosages used in men Route Medication Major brand names Form Dosage Oral: Testosterone a – Tablet: 400–800 mg/day (in divided doses) Testosterone undecanoate: Andriol, Jatenzo: Capsule: 40–80 mg/2–4× day (with meals) Methyltestosterone b: Android, Metandren, Testred: Tablet: 10–50 mg/day ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
However, replacement therapy, a similar treatment, can cost over $300,000 per year, for life. [4] In 2015, uniQure dropped its plans for approval in the US and exclusively licensed rights to sell the drug in Europe to Chiesi Farmaceutici for €31 million. [8] [4] As of 2016, only one person had received the drug outside of a clinical trial. [8]
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The drug is a prodrug of testosterone, the biological ligand of the androgen receptor (AR) and hence is an androgen and anabolic steroid. [16] [11] It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization and suitable for androgen replacement therapy. [11]
Omalizumab is the drug therapy used to deliver the anti-immunoglobulin E antibodies. Omalizumab is a human anti-IgE monoclonal antibody. It blocks IgE-mediated reactions and reduces asthma symptoms by binding to free IgE antibodies in serum. The drug is delivered every 2-4 weeks depending on severity of the patient.
It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 . [6] Durvalumab is an immune checkpoint inhibitor drug. [10] It was approved in for medical use in the United States in May 2017, [6] [9] [11] [12] and in the European Union in September 2018. [7]
Anti-D is recommended as a first-line therapy for ITP, along with corticosteroids and intravenous immune globulin (IVIG). [20] [22] [WinRho SDF is an anti-D manufactured, distributed and marketed by Cangene in the US.